Versão BETA

Acesso livre
Acesso livre

Alergia e Imunologia

Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, não houve evidência de diferenças na recuperação após tratamento inicial com imunoglobulina intravenosa (IGIV) isolada, IGIV com glicocorticoides ou glicocorticoides isolados.

18 Jun, 2021 | 10:42h

Treatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics

Comentários: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London E Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre


Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, o tratamento inicial com imunoglobulina intravenosa (IGIV) e glicocorticoides foi associado com menor risco de disfunção cardiovascular nova ou persistente em comparação ao tratamento com IGIV isolada.

18 Jun, 2021 | 10:40h

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics


Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.

17 Jun, 2021 | 11:06h

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine

Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

 

Comentário no Twitter:

 


[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.

17 Jun, 2021 | 11:04h

Comunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre

 

Comentário no Twitter

 


Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 11:00h

Myocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation

Comentário: Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients – News Medical

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 10:58h

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings – JACC: Cardiovascular Imaging

Comentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 10:57h

Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination – Pediatrics

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Perspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”

16 Jun, 2021 | 10:52h

A long-term perspective on immunity to COVID – Nature


[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.

15 Jun, 2021 | 11:35h

Comunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox

 

Comentário no Twitter (fio – clique para saber mais)

 


[Preprint] 2 doses de vacina contra Covid (Pfizer-BioNTech ou Oxford-AstraZeneca) são altamente eficazes contra hospitalização decorrente de infecção pela variante Delta.

15 Jun, 2021 | 11:32h

Comunicado de imprensa: Vaccines highly effective against hospitalisation from Delta variant – Public Health England

Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.